Lymphoma Hub continues to enhance global knowledge of lymphoma throughout 2021

Press Release: Available for Immediate Release

The Lymphoma Hub, run by Scientific Education Support in partnership with the European Lymphoma Institute, has continued to promote significant developments in the treatment and research of lymphoma throughout Quarter 2 of 2021. The hub has provided up-to-date, unbiased material for healthcare professionals in the lymphoma and chronic lymphocytic leukemia (CLL) setting.

Throughout Quarter 2, the Lymphoma Hub has covered the advances and caveats in the treatment of elderly patients with lymphoma as an educational theme. The focus of the coverage has included updated results from clinical trials, novel prognostic techniques, as well as the management of lymphoma in the elderly population.

Speaking about the impact of the hub’s activity, Mia Hill, IME director at Scientific Education Support, said:

“In 2021, the Lymphoma Hub continues to adapt to the virtual climate, remotely covering the American Society of Pediatric Hematology/Oncology (ASPHO), Acute Leukemia Forum, American Society of Clinical Oncology (ASCO), and 26th European Hematology Association annual meetings, and the 16th International Conference on Malignant Lymphoma (ICML). The Lymphoma Hub provided a combination of live and on-demand social media coverage of key sessions and conducted interviews with experts in the field of lymphoma and CLL. Furthermore, in May 2021, the Lymphoma Hub held a successful steering committee meeting to discuss the impact of currently available materials and to identify further areas of interest.”

The Lymphoma Hub was also delighted to host a virtual satellite symposium at the 16th ICML, further demonstrating its adaptability. The symposium focused on the sequencing of therapies in high-risk relapsed/refractory lymphoma and CLL and included talks from an impressive panel of international experts: Francesc Bosch, Andrew Davies, Loretta Nastoupil, and Steven Le Gouill. The symposium was hosted by Lymphoma Hub Chair Gilles Salles, who wrapped up with a captivating roundtable discussion.

Reflecting on the challenges the hub has faced throughout 2021, Mia Neve said:

“Adapting to an ever-changing COVID-19 environment has been a key challenge for everyone involved with the Lymphoma Hub, but we remain dedicated to bringing healthcare professionals the latest information regarding COVID-19 and its implications in the lymphoma setting, as well as keeping on top of the unmet medical needs in the field.

The Lymphoma Hub owes thanks to its supporters—Bristol Myers Squibb, Incyte, Roche Genentech, Novartis, Epizyme, Karyopharm, TG Therapeutics —without whom our work would not be possible. We would also like to give an extended thank you and welcome to ADC Therapeutics (Contributor), the Lymphoma Hub’s latest supporter.”

ENDS

For more information on the Lymphoma Hub, please visit lymphomahub.com. For media enquiries or to explore collaboration opportunities, please contact secretariat@scientificeducationsupport.com or Barry.Connolly@scientificeducationsupport.com.

NOTES TO EDITOR

About lymphoma

Lymphoma is a cancer that begins in infection-fighting cells of the immune system, called lymphocytes. These cells are in the lymph nodes, spleen, thymus, bone marrow, and other parts of the body. When you have lymphoma, lymphocytes change and grow out of control. There are two main types of lymphoma: non-Hodgkin (most people with lymphoma have this type) and Hodgkin.

About the Lymphoma Hub

The Lymphoma Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education in lymphoma and CLL. Our aim is to enhance knowledge in lymphoma and CLL through the multichannel dissemination of global advances related to their classification, diagnosis, treatment, and management.

The Lymphoma Hub is the solution for a time-stretched HCP to easily access impactful information that expedites learning and empowers their treatment decisions. Informed by patients, curated by world leaders, and endorsed by expert societies the Lymphoma Hub supports HCPs worldwide.

The Lymphoma Hub shares new data, evidence-based articles, therapy approvals, expert opinions, and international congress coverage to treatment teams and researchers around the world.

Lymphoma Hub supporters

Funding for our hubs are made possible through financial support from the pharmaceutical industry. ​All content is developed by SES in collaboration with an expert Steering Committee.​All content is independent, and the educational supporters are allowed no influence on the content.​

• Bristol Myers Squibb
• Incyte
• Roche Genentech
• Novartis
• DC Therapeutics
• Epizyme
• Karyopharm Therapeutics
• TG Therapeutics

If you are interested in becoming a Lymphoma Hub supporter, please contact secretariat@scientificeducationsupport.com

About Scientific Education Support (SES)

SES is a medical education company with projects such as community physician education through our therapy hubs, community awareness and education through our ‘KNOW’ education initiatives, and academic researcher education through Entrepreneurs in Clinical Academia (ECA) programs.

Scientific Education Support already has a portfolio of successful websites supporting the advancement of medical education in the field of hemato-oncology, which includes the ALL Hub, AML Hub, Multiple Myeloma Hub, GvHD Hub, MPN Hub, and MDS Hub.

About The European Lymphoma Institute (ELI)

Lymphoma, the sixth cancer worldwide in terms of incidence, is a complex disease. The European Lymphoma Institute (ELI) regroups top European specialists in the field of lymphoma within a net dedicated to research, training, and education. To date, thirteen European academic research groups have come together in an effort to define strategies to analyze and characterize this cancer, common diagnostic procedures, and therapeutic standards, as well as to facilitate clinical and fundamental research at the European level.

As a result of this collaborative work—truly unique in the world—together, we are helping to bring lymphoma research forward and guarantee equal access for all patients to the best possible care.